{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:55:00Z","timestamp":1791046500230,"version":"4.1.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A major obstacle to chemotherapeutic success in cancer treatment is the development of drug resistance. This occurs when a tumour fails to reduce in size after treatment or when there is clinical relapse after an initial positive response to treatment. A unique and serious type of resistance is multidrug resistance (MDR). MDR causes the simultaneous cross resistance to unrelated drugs used in chemotherapy. MDR can be acquired through genetic alterations following drug exposure, or as discovered by us, through alternative pathways mediated by the transfer of functional MDR proteins and nucleic acids by extracellular vesicles (M Bebawy V Combes E Lee R Jaiswal J Gong A Bonhoure GE Grau, 23 9 1643 1649, 2009).<\/jats:p><jats:p>Multiple myeloma is an incurable cancer of bone marrow plasma cells. Treatment involves high dose combination chemotherapy and patient response is unpredictable and variable due to the presence of multisite clonal tumour infiltrates. This clonal heterogeneity can contribute to the development of MDR. There is currently no approved clinical test for the minimally invasive testing of MDR in myeloma.<\/jats:p><jats:p>Extracellular vesicles comprise a group of heterogeneous cell-derived membranous structures which include; exosomes, microparticles (microvesicles), migrasomes and apoptotic bodies. Extracellular vesicles serve an important role in cellular communication through the intercellular transfer of cellular protein, nucleic acid and lipid cargo. Of these, microparticles (MPs) originate from the cell plasma membrane and vary in size from 0.1-1um. We have previously shown that MPs confer MDR through the transfer of resistance proteins and nucleic acids. A test for the early detection of MDR would benefit clinical decision making, improve survival and support rational drug use. This review focuses on microparticles as novel clinical biomarkers for the detection of MDR in Myeloma and discusses their role in the therapeutic management of the disease.<\/jats:p>","DOI":"10.1186\/s12943-022-01683-w","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T08:02:22Z","timestamp":1682755342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Circulating biosignatures in multiple myeloma and their role in multidrug resistance"],"prefix":"10.1186","volume":"22","author":[{"given":"S. Rajeev","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bebawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"1683_CR1","unstructured":"2019., A. I. o. H. a. W. C. i. A. (2019). Cancer in Australia 2019. Cancer series no.119., Cat. no. CAN 123. Canberra: AIHW."},{"issue":"17","key":"1683_CR2","first-page":"4676","volume":"54","author":"MR Abbaszadegan","year":"1994","unstructured":"Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res. 1994;54(17):4676\u20139.","journal-title":"Cancer Res"},{"key":"1683_CR3","doi-asserted-by":"crossref","unstructured":"Abildgaard, N., Bentzen, S. M., Nielsen, J. L., & Heickendorff, L. (1997). Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Br J Haematol, 96(1), 103\u2013110.","DOI":"10.1046\/j.1365-2141.1997.8672495.x"},{"issue":"2","key":"1683_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/187152010790909344","volume":"10","author":"JR Agarwal","year":"2010","unstructured":"Agarwal JR, Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem. 2010;10(2):116\u201320.","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"1683_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1046\/j.1365-2257.2003.00492.x","volume":"25","author":"M Alexandrakis","year":"2003","unstructured":"Alexandrakis M, Passam F, Ganotakis E, Sfiridaki K, Xilouri I, Perisinakis K, Kyriakou D. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol. 2003;25(1):41\u20136.","journal-title":"Clin Lab Haematol"},{"issue":"1","key":"1683_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1160\/TH10-03-0187","volume":"105","author":"J Auwerda","year":"2011","unstructured":"Auwerda J, Yuana Y, Osanto S, de Maat M, Sonneveld P, Bertina R, Leebeek F. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011;105(1):14\u201320.","journal-title":"Thromb Haemost"},{"issue":"29","key":"1683_CR7","first-page":"4648","volume":"21","author":"Q-P Bao","year":"2017","unstructured":"Bao Q-P, Li H-M, Li X-J, Yan Y-H. Biological characteristics of side population cells in multiple myeloma U266 cell line in relation to drug resistance. Chinese Journal of Tissue Engineering Research. 2017;21(29):4648.","journal-title":"Chinese Journal of Tissue Engineering Research"},{"issue":"10","key":"1683_CR8","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/1097-0142(19911115)68:10<2241::AID-CNCR2820681024>3.0.CO;2-0","volume":"68","author":"R Bartl","year":"1991","unstructured":"Bartl R, Frisch B, Diem H, Mundel M, Nagel D, Lamerz R, Fateh-Moghadam A. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma. Cancer. 1991;68(10):2241\u201350.","journal-title":"Cancer"},{"issue":"10","key":"1683_CR9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/modpathol.3880435","volume":"14","author":"IB Bayer-Garner","year":"2001","unstructured":"Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 2001;14(10):1052\u20138. https:\/\/doi.org\/10.1038\/modpathol.3880435.","journal-title":"Mod Pathol"},{"issue":"9","key":"1683_CR10","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/leu.2009.76","volume":"23","author":"M Bebawy","year":"2009","unstructured":"Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, Grau GE. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia. 2009;23(9):1643\u20139. https:\/\/doi.org\/10.1038\/leu.2009.76.","journal-title":"Leukemia"},{"key":"1683_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.micron.2013.08.010","volume":"54\u201355","author":"T Benameur","year":"2013","unstructured":"Benameur T, Chappard D, Fioleau E, Andriantsitohaina R, Martinez MC, Clere N, Marchand-Libouban H. Plasma cells release membrane microparticles in a mouse model of multiple myeloma. Micron. 2013;54\u201355:75\u201381. https:\/\/doi.org\/10.1016\/j.micron.2013.08.010.","journal-title":"Micron"},{"issue":"9","key":"1683_CR12","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.v99.9.3163","volume":"99","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Salmon SE. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99(9):3163\u20138. https:\/\/doi.org\/10.1182\/blood.v99.9.3163.","journal-title":"Blood"},{"issue":"1","key":"1683_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1146\/annurev.biochem.68.1.729","volume":"68","author":"M Bernfield","year":"1999","unstructured":"Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68(1):729\u201377. https:\/\/doi.org\/10.1146\/annurev.biochem.68.1.729.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"1683_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.cb.08.110192.002053","volume":"8","author":"M Bernfield","year":"1992","unstructured":"Bernfield M, Kokenyesi R, Kato M, Hinkes M, Spring J, Gallo R, Lose E. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 1992;8(1):365\u201393.","journal-title":"Annu Rev Cell Biol"},{"issue":"6","key":"1683_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1683_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1365-2141.1993.tb03058.x","volume":"84","author":"R Brown","year":"1993","unstructured":"Brown R, Joshua D, Nelson M, Gibson J, Dunn J, MacLennan I. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial. Br J Haematol. 1993;84(2):238\u201341.","journal-title":"Br J Haematol"},{"key":"1683_CR17","unstructured":"Brown, R. D., Joshua, D. E., Nelson, M., Gibson, J., Dunn, J., & MacLennan, I. C. M. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V Trial."},{"key":"1683_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.34","volume":"3","author":"C Bryant","year":"2013","unstructured":"Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, Joshua DE. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance. Blood Cancer J. 2013;3: e148. https:\/\/doi.org\/10.1038\/bcj.2013.34.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1683_CR19","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/ijms18061183","volume":"18","author":"A Caivano","year":"2017","unstructured":"Caivano A, La Rocca F, Laurenzana I, Trino S, De Luca L, Lamorte D, Musto P. Extracellular vesicles in hematological malignancies: from biology to therapy. Int J Mol Sci. 2017;18(6):1183.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1683_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1124\/dmd.113.056176","volume":"42","author":"R Callaghan","year":"2014","unstructured":"Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos. 2014;42(4):623\u201331. https:\/\/doi.org\/10.1124\/dmd.113.056176.","journal-title":"Drug Metab Dispos"},{"key":"1683_CR21","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/S0049-3848(10)70021-9","volume":"125","author":"D Castellana","year":"2010","unstructured":"Castellana D, Toti F, Freyssinet J-M. Membrane microvesicles: macromessengers in cancer disease and progression. Thromb Res. 2010;125:S84\u20138.","journal-title":"Thromb Res"},{"key":"1683_CR22","doi-asserted-by":"crossref","unstructured":"Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., . . . Adli, M. (2011). Initial genome sequencing and analysis of multiple myeloma. nature, 471(7339), 467\u2013472.","DOI":"10.1038\/nature09837"},{"issue":"3","key":"1683_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12288-017-0822-z","volume":"33","author":"G Chatterjee","year":"2017","unstructured":"Chatterjee G, Gujral S, Subramanian PG, Tembhare PR. Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian J Hematol Blood Transfus. 2017;33(3):303\u201315. https:\/\/doi.org\/10.1007\/s12288-017-0822-z.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"1683_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07077-9","volume":"20","author":"T Ching","year":"2020","unstructured":"Ching T, Duncan ME, Newman-Eerkes T, McWhorter MM, Tracy JM, Steen MS, Vignali M. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020;20(1):1\u201315.","journal-title":"BMC Cancer"},{"issue":"8","key":"1683_CR25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1055\/s-0031-1297372","volume":"37","author":"A Coppola","year":"2011","unstructured":"Coppola A, Tufano A, Di Capua M, Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost. 2011;37(8):929\u201345. https:\/\/doi.org\/10.1055\/s-0031-1297372.","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"1683_CR26","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Fitzmaurice C. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1683_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.1985.140","volume":"52","author":"J Cuzick","year":"1985","unstructured":"Cuzick J, Cooper E, MacLennan I. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer. 1985;52(1):1.","journal-title":"Br J Cancer"},{"issue":"4","key":"1683_CR28","doi-asserted-by":"publisher","first-page":"854","DOI":"10.2214\/AJR.13.10724","volume":"203","author":"M D'Anastasi","year":"2014","unstructured":"D\u2019Anastasi M, Notohamiprodjo M, Schmidt GP, D\u00fcrr H-R, Reiser MF, Baur-Melnyk A. Tumor Load in Patients With Multiple Myeloma: \u03b22-Microglobulin Levels Versus Whole-Body MRI. Am J Roentgenol. 2014;203(4):854\u201362.","journal-title":"Am J Roentgenol"},{"issue":"4","key":"1683_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1046\/j.1365-2141.1997.3793193.x","volume":"99","author":"F Davies","year":"1997","unstructured":"Davies F, Jack A, Morgan G. The use of biological variables to predict outcome in multiple myeloma. Br J Haematol. 1997;99(4):719\u201325.","journal-title":"Br J Haematol"},{"issue":"3","key":"1683_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/14737159.2019.1583103","volume":"19","author":"L De Luca","year":"2019","unstructured":"De Luca L, Laurenzana I, Trino S, Lamorte D, Caivano A, Musto P. An update on extracellular vesicles in multiple myeloma: A focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers. Expert Rev Mol Diagn. 2019;19(3):249\u201358.","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"1683_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.tips.2019.01.006","volume":"40","author":"G De Rubis","year":"2019","unstructured":"De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol Sci. 2019;40(3):172\u201386. https:\/\/doi.org\/10.1016\/j.tips.2019.01.006.","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"1683_CR32","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2004-03-1095","volume":"106","author":"I del Conde","year":"2005","unstructured":"del Conde I, Shrimpton CN, Thiagarajan P, L\u00f3pez JA. Tissue-factor\u2013bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106(5):1604\u201311.","journal-title":"Blood"},{"issue":"2","key":"1683_CR33","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1365-2141.1997.3893203.x","volume":"99","author":"MV Dhodapkar","year":"1997","unstructured":"Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol. 1997;99(2):368\u201371.","journal-title":"Br J Haematol"},{"issue":"12","key":"1683_CR34","doi-asserted-by":"publisher","first-page":"931","DOI":"10.7326\/0003-4819-115-12-931","volume":"115","author":"MA Dimopoulos","year":"1991","unstructured":"Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931\u20135.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1683_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1634\/theoncologist.1-3-151","volume":"1","author":"C Duhem","year":"1996","unstructured":"Duhem C, Ries F, Dicato M. What Does Multidrug Resistance (MDR) Expression Mean in the Clinic? Oncologist. 1996;1(3):151\u20138.","journal-title":"Oncologist"},{"issue":"2","key":"1683_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/bjc.1992.266","volume":"66","author":"I Elomaa","year":"1992","unstructured":"Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992;66(2):337.","journal-title":"Br J Cancer"},{"issue":"12","key":"1683_CR37","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/rheumatology\/ken373","volume":"47","author":"U Erdbruegger","year":"2008","unstructured":"Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, Woywodt A, Haubitz M. Diagnostic role of endothelial microparticles in vasculitis. Rheumatology. 2008;47(12):1820\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/ken373.","journal-title":"Rheumatology"},{"key":"1683_CR38","doi-asserted-by":"publisher","unstructured":"Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996). Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer, 32a(6), 1082\u20131088. doi:https:\/\/doi.org\/10.1016\/0959-8049(96)00111-6","DOI":"10.1016\/0959-8049(96)00111-6"},{"issue":"4","key":"1683_CR39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1083\/jcb.148.4.811","volume":"148","author":"ML Fitzgerald","year":"2000","unstructured":"Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. Shedding of syndecan-1 and-4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3\u2013sensitive metalloproteinase. J Cell Biol. 2000;148(4):811\u201324.","journal-title":"J Cell Biol"},{"issue":"10","key":"1683_CR40","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, Orfao A. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094\u2013103. https:\/\/doi.org\/10.1038\/leu.2017.29.","journal-title":"Leukemia"},{"issue":"7","key":"1683_CR41","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1046\/j.1538-7836.2003.00309.x","volume":"1","author":"JM Freyssinet","year":"2003","unstructured":"Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost. 2003;1(7):1655\u201362.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"1683_CR42","first-page":"2581","volume":"38","author":"C Friend","year":"1978","unstructured":"Friend C, Marovitz W, Henle G, Henle W, Tsuei D, Hirschhorn K, Cuttner J. Observations on cell lines derived from a patient with Hodgkin\u2019s disease. Can Res. 1978;38(8):2581\u201391.","journal-title":"Can Res"},{"key":"1683_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12020","author":"JG Gaultney","year":"2012","unstructured":"Gaultney JG, Franken MG, Tan SS, Redekop WK, Huijgens PC, Sonneveld P, Uyl-de Groot CA. Real-world health care costs of relapsed\/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther. 2012. https:\/\/doi.org\/10.1111\/jcpt.12020.","journal-title":"J Clin Pharm Ther"},{"key":"1683_CR44","doi-asserted-by":"crossref","unstructured":"Gelderman, M. P., & Simak, J. (2008). Flow Cytometric Analysis of Cell Membrane Microparticles. In (Vol. 484, pp. 79\u201393).","DOI":"10.1007\/978-1-59745-398-1_6"},{"key":"1683_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/561571","volume":"2014","author":"I Giusti","year":"2014","unstructured":"Giusti I, Dolo V. Extracellular vesicles in prostate cancer: new future clinical strategies? Biomed Res Int. 2014;2014: 561571. https:\/\/doi.org\/10.1155\/2014\/561571.","journal-title":"Biomed Res Int"},{"key":"1683_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semcdb.2015.03.009","volume":"40","author":"J Gong","year":"2015","unstructured":"Gong J, Jaiswal R, Dalla P, Luk F, Bebawy M. Microparticles in cancer: A review of recent developments and the potential for clinical application. Semin Cell Dev Biol. 2015;40:35\u201340. https:\/\/doi.org\/10.1016\/j.semcdb.2015.03.009.","journal-title":"Semin Cell Dev Biol"},{"issue":"3","key":"1683_CR47","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ctrv.2011.06.005","volume":"38","author":"J Gong","year":"2012","unstructured":"Gong J, Jaiswal R, Mathys JM, Combes V, Grau GE, Bebawy M. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev. 2012;38(3):226\u201334. https:\/\/doi.org\/10.1016\/j.ctrv.2011.06.005.","journal-title":"Cancer Treat Rev"},{"key":"1683_CR48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fonc.2014.00220","volume":"4","author":"J Gong","year":"2014","unstructured":"Gong J, Luk F, Jaiswal R, Bebawy M. Microparticles Mediate the Intercellular Regulation of microRNA-503 and Proline-Rich Tyrosine Kinase 2 to Alter the Migration and Invasion Capacity of Breast Cancer Cells. Front Oncol. 2014;4:220. https:\/\/doi.org\/10.3389\/fonc.2014.00220.","journal-title":"Front Oncol"},{"issue":"1\u20133","key":"1683_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejphar.2013.09.044","volume":"721","author":"J Gong","year":"2013","unstructured":"Gong J, Luk F, Jaiswal R, George AM, Grau GE, Bebawy M. Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance. Eur J Pharmacol. 2013;721(1\u20133):116\u201325. https:\/\/doi.org\/10.1016\/j.ejphar.2013.09.044.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1683_CR50","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1096\/fj.02-0739rev","volume":"17","author":"M Gotte","year":"2003","unstructured":"Gotte M. Syndecans in inflammation. The FASEB journal\u202f: official publication of the Federation of American Societies for Experimental Biology. 2003;17(6):575\u201391. https:\/\/doi.org\/10.1096\/fj.02-0739rev.","journal-title":"The FASEB journal : official publication of the Federation of American Societies for Experimental Biology"},{"issue":"15","key":"1683_CR51","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/jco.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320. https:\/\/doi.org\/10.1200\/jco.2005.04.242.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1683_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/sj.bmt.1704779","volume":"35","author":"S Gupta","year":"2005","unstructured":"Gupta S, Zhou P, Hassoun H, Kewalramani T, Reich L, Costello S, Teruya-Feldstein J. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Bone Marrow Transplant. 2005;35(5):441\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1683_CR53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/ki.1987.255","volume":"32","author":"HCS Gus","year":"1987","unstructured":"Gus HCS, Van Eps LS. bold beta 2-microglobulin: Its significance in the evaluation of renal function. Kidney Int. 1987;32:635\u201341.","journal-title":"Kidney Int"},{"issue":"5","key":"1683_CR54","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.12563","volume":"163","author":"R Hajek","year":"2013","unstructured":"Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol. 2013;163(5):551\u201364.","journal-title":"Br J Haematol"},{"issue":"20","key":"1683_CR55","first-page":"3013","volume":"13","author":"SW Harshman","year":"2013","unstructured":"Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Benson DM. Characterization of multiple myeloma vesicles by label-free relative quantitation. Proteomics. 2013;13(20):3013\u201329.","journal-title":"Proteomics"},{"issue":"7","key":"1683_CR56","first-page":"539","volume":"1","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Anderson KC. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002;1(7):539\u201344.","journal-title":"Mol Cancer Ther"},{"issue":"42","key":"1683_CR57","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma. Oncogene. 2001;20(42):5991\u20136000. https:\/\/doi.org\/10.1038\/sj.onc.1204833.","journal-title":"Oncogene"},{"key":"1683_CR58","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1042\/bj3210265","volume":"321","author":"N Hooper","year":"1997","unstructured":"Hooper N, Karran E, Turner A. Membrane protein secretases. Biochem J. 1997;321:265\u201379.","journal-title":"Biochem J"},{"key":"1683_CR59","doi-asserted-by":"crossref","unstructured":"Huang, J., Chan, S. C., Lok, V., Zhang, L., Lucero-Prisno III, D. E., Xu, W., . . . Wong, M. C. (2022). The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. The Lancet Haematology.","DOI":"10.1016\/S2352-3026(22)00165-X"},{"issue":"2","key":"1683_CR60","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1182\/blood-2005-06-2517","volume":"107","author":"CA Huff","year":"2006","unstructured":"Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006;107(2):431\u20134. https:\/\/doi.org\/10.1182\/blood-2005-06-2517.","journal-title":"Blood"},{"issue":"1","key":"1683_CR61","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1096\/fj.11-186817","volume":"26","author":"R Jaiswal","year":"2012","unstructured":"Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R, Bebawy M. Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J. 2012;26(1):420\u20139. https:\/\/doi.org\/10.1096\/fj.11-186817.","journal-title":"FASEB J"},{"issue":"1","key":"1683_CR62","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1096\/fj.11-186817","volume":"26","author":"R Jaiswal","year":"2012","unstructured":"Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R, Bebawy M. Microparticle-associated nucleic acids mediate trait dominance in cancer. The FASEB journal\u202f: official publication of the Federation of American Societies for Experimental Biology. 2012;26(1):420\u20139. https:\/\/doi.org\/10.1096\/fj.11-186817.","journal-title":"The FASEB journal : official publication of the Federation of American Societies for Experimental Biology"},{"issue":"1","key":"1683_CR63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12885-017-3102-2","volume":"17","author":"R Jaiswal","year":"2017","unstructured":"Jaiswal R, Johnson MS, Pokharel D, Krishnan SR, Bebawy M. Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion. BMC Cancer. 2017;17(1):104. https:\/\/doi.org\/10.1186\/s12885-017-3102-2.","journal-title":"BMC Cancer"},{"issue":"4","key":"1683_CR64","doi-asserted-by":"publisher","first-page":"e61515","DOI":"10.1371\/journal.pone.0061515","volume":"8","author":"R Jaiswal","year":"2013","unstructured":"Jaiswal R, Luk F, Dalla PV, Grau GE, Bebawy M. Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS ONE. 2013;8(4):e61515. https:\/\/doi.org\/10.1371\/journal.pone.0061515.","journal-title":"PLoS ONE"},{"issue":"4","key":"1683_CR65","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2217\/fon.13.230","volume":"10","author":"R Jaiswal","year":"2014","unstructured":"Jaiswal R, Raymond Grau GE, Bebawy M. Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. Future Oncol. 2014;10(4):655\u201369. https:\/\/doi.org\/10.2217\/fon.13.230.","journal-title":"Future Oncol"},{"issue":"7","key":"1683_CR66","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1537-2995.2006.00871.x","volume":"46","author":"A Janowska-Wieczorek","year":"2006","unstructured":"Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion. 2006;46(7):1199\u2013209.","journal-title":"Transfusion"},{"issue":"10","key":"1683_CR67","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1038\/bcj.2017.90","volume":"7","author":"T Jelinek","year":"2017","unstructured":"Jelinek T, Bezdekova R, Zatopkova M, Burgos L, Simicek M, Sevcikova T, Hajek R. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J. 2017;7(10):e617. https:\/\/doi.org\/10.1038\/bcj.2017.90.","journal-title":"Blood Cancer J"},{"key":"1683_CR68","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1182\/blood-2021-153774","volume":"138","author":"M Jiang","year":"2021","unstructured":"Jiang M, Lee LW, Eckert B, Demaree A, Hewitt T. Longitudinal MRD Assessment in Real-World Multiple Myeloma Patients Using Next-Generation Sequencing (clonoSEQ\u00ae Assay). Blood. 2021;138:3783.","journal-title":"Blood"},{"issue":"4","key":"1683_CR69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0049-3848(03)00064-1","volume":"109","author":"JJ Jimenez","year":"2003","unstructured":"Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109(4):175\u201380.","journal-title":"Thromb Res"},{"key":"1683_CR70","doi-asserted-by":"crossref","unstructured":"Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease, 1994\/11\/01 Sess. 375\u2013381 (1994).","DOI":"10.3109\/10428199409049739"},{"issue":"8","key":"1683_CR71","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5694\/mja2.50129","volume":"210","author":"DE Joshua","year":"2019","unstructured":"Joshua DE, Bryant C, Dix C, Gibson J, Ho J. Biology and therapy of multiple myeloma. Med J Aust. 2019;210(8):375\u201380.","journal-title":"Med J Aust"},{"key":"1683_CR72","doi-asserted-by":"crossref","unstructured":"Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., . . . Tanaka, H. (1988). Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas.","DOI":"10.1038\/332083a0"},{"issue":"38","key":"1683_CR73","doi-asserted-by":"publisher","first-page":"26085","DOI":"10.1074\/jbc.M109.018473","volume":"284","author":"YB Khotskaya","year":"2009","unstructured":"Khotskaya YB, Dai Y, Ritchie JP, MacLeod V, Yang Y, Zinn K, Sanderson RD. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem. 2009;284(38):26085\u201395. https:\/\/doi.org\/10.1074\/jbc.M109.018473.","journal-title":"J Biol Chem"},{"issue":"12","key":"1683_CR74","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1038\/leu.2012.140","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Park CY, Medeiros BC, Weissman IL. CD19-CD45 low\/- CD38 high\/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia. 2012;26(12):2530\u20137. https:\/\/doi.org\/10.1038\/leu.2012.140.","journal-title":"Leukemia"},{"key":"1683_CR75","doi-asserted-by":"crossref","unstructured":"Klein, B., Wijdenes, J., & Zhang, X. (1991). Jourdan M, Boiron JM. Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J, Bataille R: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 78, 1198.","DOI":"10.1182\/blood.V78.5.1198.bloodjournal7851198"},{"issue":"1","key":"1683_CR76","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/ijo.2016.3516","volume":"49","author":"SR Krishnan","year":"2016","unstructured":"Krishnan SR, Jaiswal R, Brown RD, Luk F, Bebawy M. Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). Int J Oncol. 2016;49(1):33\u201350.","journal-title":"Int J Oncol"},{"issue":"1","key":"1683_CR77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neo.2015.11.011","volume":"18","author":"SR Krishnan","year":"2016","unstructured":"Krishnan SR, Luk F, Brown RD, Suen H, Kwan Y, Bebawy M. Isolation of human CD138+ microparticles from the plasma of patients with multiple myeloma. Neoplasia. 2016;18(1):25\u201332.","journal-title":"Neoplasia"},{"key":"1683_CR78","doi-asserted-by":"crossref","unstructured":"Kuranda, K., Berthon, C., Dupont, C., Wolowiec, D., Leleu, X., Polakowska, R., . . . Quesnel, B. (2010). A subpopulation of malignant CD34+ CD138+ B7-H1+ plasma cells is present in multiple myeloma patients. Experimental hematology, 38(2), 124\u2013131. e124.","DOI":"10.1016\/j.exphem.2009.11.008"},{"issue":"1","key":"1683_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3\u20139. https:\/\/doi.org\/10.1038\/leu.2008.291.","journal-title":"Leukemia"},{"issue":"4","key":"1683_CR80","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","volume":"9","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009;9(4):278\u201388. https:\/\/doi.org\/10.3816\/CLM.2009.n.056.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"5","key":"1683_CR81","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/leu.2011.290","volume":"26","author":"S Lamorte","year":"2012","unstructured":"Lamorte S, Ferrero S, Aschero S, Monitillo L, Bussolati B, Omede P, Camussi G. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia. 2012;26(5):1081\u201390. https:\/\/doi.org\/10.1038\/leu.2011.290.","journal-title":"Leukemia"},{"issue":"8","key":"1683_CR82","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.4161\/rna.25281","volume":"10","author":"CCY Li","year":"2013","unstructured":"Li CCY, Eaton SA, Young PE, Lee M, Shuttleworth R, Humphreys DT, Suter CM. Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells. RNA Biol. 2013;10(8):1333\u201344. https:\/\/doi.org\/10.4161\/rna.25281.","journal-title":"RNA Biol"},{"issue":"2","key":"1683_CR83","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/aps.2013.141","volume":"35","author":"Y Liu","year":"2014","unstructured":"Liu Y, Zhu XJ, Zeng C, Wu PH, Wang HX, Chen ZC, Li QB. Microvesicles secreted from human multiple myeloma cells promote angiogenesis. Acta Pharmacol Sin. 2014;35(2):230\u20138. https:\/\/doi.org\/10.1038\/aps.2013.141.","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"1683_CR84","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1080\/10428190802272676","volume":"49","author":"YS Loh","year":"2008","unstructured":"Loh YS, Mo S, Brown RD, Yamagishi T, Yang S, Joshua DE, Sze DM. Presence of Hoechst low side populations in multiple myeloma. Leuk Lymphoma. 2008;49(9):1813\u20136. https:\/\/doi.org\/10.1080\/10428190802272676.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1683_CR85","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1158\/1078-0432.ccr-10-1805","volume":"17","author":"S Lonial","year":"2011","unstructured":"Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011;17(6):1264\u201377. https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-1805.","journal-title":"Clin Cancer Res"},{"key":"1683_CR86","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.phrs.2013.07.009","volume":"76","author":"JF Lu","year":"2013","unstructured":"Lu JF, Luk F, Gong J, Jaiswal R, Grau GE, Bebawy M. Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways. Pharmacol Res. 2013;76:77\u201383. https:\/\/doi.org\/10.1016\/j.phrs.2013.07.009.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1683_CR87","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s13346-016-0353-4","volume":"7","author":"JF Lu","year":"2017","unstructured":"Lu JF, Pokharel D, Bebawy M. A novel mechanism governing the transcriptional regulation of ABC transporters in MDR cancer cells. Drug Deliv Transl Res. 2017;7(2):276\u201385. https:\/\/doi.org\/10.1007\/s13346-016-0353-4.","journal-title":"Drug Deliv Transl Res"},{"key":"1683_CR88","doi-asserted-by":"crossref","unstructured":"Luoni, R., Ucci, G., Riccardi, A., Gobbi, P., Avato, F. M., Vignale, C., & Ascari, E. (1992). Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma. Cancer, 69(6), 1368\u20131372.","DOI":"10.1002\/1097-0142(19920315)69:6<1368::AID-CNCR2820690611>3.0.CO;2-R"},{"issue":"1","key":"1683_CR89","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/0008-5472.can-07-3096","volume":"68","author":"W Matsui","year":"2008","unstructured":"Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, Jones RJ. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68(1):190\u20137. https:\/\/doi.org\/10.1158\/0008-5472.can-07-3096.","journal-title":"Cancer Res"},{"issue":"2","key":"1683_CR90","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/0022-3859.132319","volume":"60","author":"O Mehtap","year":"2014","unstructured":"Mehtap O, Atesoglu E, Tarkun P, Hacihanefioglu A, Dolasik I, Musul M. IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis. J Postgrad Med. 2014;60(2):141.","journal-title":"J Postgrad Med"},{"key":"1683_CR91","doi-asserted-by":"crossref","unstructured":"Minciacchi, V. R., Freeman, M. R., & Di Vizio, D. (2015). Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Paper presented at the Seminars in cell & developmental biology.","DOI":"10.1016\/j.semcdb.2015.02.010"},{"issue":"1","key":"1683_CR92","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/atvbaha.109.200956","volume":"31","author":"O Morel","year":"2011","unstructured":"Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):15\u201326. https:\/\/doi.org\/10.1161\/atvbaha.109.200956.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1683_CR93","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/01.moh.0000131441.10020.87","volume":"11","author":"O Morel","year":"2004","unstructured":"Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol. 2004;11(3):156\u201364.","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"1683_CR94","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1021\/acsptsci.1c00074","volume":"4","author":"RL Mynott","year":"2021","unstructured":"Mynott RL, Wallington-Beddoe CT. Drug and solute transporters in mediating resistance to novel therapeutics in multiple myeloma. ACS Pharmacology & Translational Science. 2021;4(3):1050\u201365.","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"3","key":"1683_CR95","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/carcin\/bgp001","volume":"30","author":"V Nikolova","year":"2009","unstructured":"Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, Gotte M. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009;30(3):397\u2013407. https:\/\/doi.org\/10.1093\/carcin\/bgp001.","journal-title":"Carcinogenesis"},{"issue":"Suppl 5","key":"1683_CR96","first-page":"S10","volume":"11","author":"V Nuessler","year":"1997","unstructured":"Nuessler V, Gieseler F, Gullis E, Pelka-Fleischer R, Stotzer O, Zwierzina H, Wilmanns W. Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease. Leukemia. 1997;11(Suppl 5):S10-14.","journal-title":"Leukemia"},{"issue":"2","key":"1683_CR97","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1309\/617d-wb5g-nfwx-hw4l","volume":"121","author":"FP O'Connell","year":"2004","unstructured":"O\u2019Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121(2):254\u201363. https:\/\/doi.org\/10.1309\/617d-wb5g-nfwx-hw4l.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"1683_CR98","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","volume":"119","author":"B Paiva","year":"2012","unstructured":"Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, San Miguel JF. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687\u201391. https:\/\/doi.org\/10.1182\/blood-2011-07-370460.","journal-title":"Blood"},{"issue":"6","key":"1683_CR99","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.ccr-10-1925","volume":"17","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res. 2011;17(6):1253\u201363. https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-1925.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1683_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013415","volume":"5","author":"JB Pankoui Mfonkeu","year":"2010","unstructured":"Pankoui Mfonkeu JB, Gouado I, Fotso Kuat\u00e9 H, Zambou O, Amvam Zollo PH, Grau GER, Combes V. Elevated Cell-Specific Microparticles Are a Biological Marker for Cerebral Dysfunctions in Human Severe Malaria. PLoS ONE. 2010;5(10): e13415. https:\/\/doi.org\/10.1371\/journal.pone.0013415.","journal-title":"PLoS ONE"},{"issue":"7","key":"1683_CR101","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1073\/pnas.69.7.1697","volume":"69","author":"PA Peterson","year":"1972","unstructured":"Peterson PA, Cunningham BA, Bergg\u00e5rd I, Edelman GM. \u03b22-Microglobulin\u2014a free immunoglobulin domain. Proc Natl Acad Sci. 1972;69(7):1697\u2013701.","journal-title":"Proc Natl Acad Sci"},{"issue":"5\u20136","key":"1683_CR102","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3109\/10428199509056847","volume":"17","author":"LM Pilarski","year":"1995","unstructured":"Pilarski LM, Belch AR. Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. Leuk Lymphoma. 1995;17(5\u20136):367\u201374. https:\/\/doi.org\/10.3109\/10428199509056847.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1683_CR103","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0092-8674(81)90318-4","volume":"24","author":"HL Ploegh","year":"1981","unstructured":"Ploegh HL, Orr HT, Strominger JL. Major histocompatibility antigens: the human (HLA-A,-B,-C) and murine (H-2K, H-2D) class I molecules. Cell. 1981;24(2):287\u201399.","journal-title":"Cell"},{"key":"1683_CR104","doi-asserted-by":"publisher","DOI":"10.3402\/jev.v3.24384","author":"D Pokharel","year":"2014","unstructured":"Pokharel D, Padula MP, Lu JF, Tacchi JL, Luk F, Djordjevic SP, Bebawy M. Proteome analysis of multidrug-resistant, breast cancer-derived microparticles. J Extracell Vesicles 3. 2014. https:\/\/doi.org\/10.3402\/jev.v3.24384.","journal-title":"J Extracell Vesicles 3"},{"issue":"8","key":"1683_CR105","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1089\/omi.2016.0072","volume":"20","author":"D Pokharel","year":"2016","unstructured":"Pokharel D, Wijesinghe P, Oenarto V, Lu JF, Sampson DD, Kennedy BF, Bebawy M. Deciphering Cell-to-Cell Communication in Acquisition of Cancer Traits: Extracellular Membrane Vesicles Are Regulators of Tissue Biomechanics. OMICS. 2016;20(8):462\u20139. https:\/\/doi.org\/10.1089\/omi.2016.0072.","journal-title":"OMICS"},{"issue":"2","key":"1683_CR106","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1046\/j.1365-2141.1996.d01-1470.x","volume":"92","author":"K Pulkki","year":"1996","unstructured":"Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group Br J Haematol. 1996;92(2):370\u20134.","journal-title":"Finnish Leukaemia Group Br J Haematol"},{"issue":"3","key":"1683_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-0304-7","volume":"10","author":"S Rajeev Krishnan","year":"2020","unstructured":"Rajeev Krishnan S, De Rubis G, Suen H, Joshua D, Lam Kwan Y, Bebawy M. A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma. Blood Cancer J. 2020;10(3):1\u201311.","journal-title":"Blood Cancer J"},{"issue":"12","key":"1683_CR108","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1683_CR109","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1084\/jem.183.3.1161","volume":"183","author":"G Raposo","year":"1996","unstructured":"Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief C, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183(3):1161\u201372.","journal-title":"J Exp Med"},{"issue":"1","key":"1683_CR110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.1999.01301.x","volume":"105","author":"T Rasmussen","year":"1999","unstructured":"Rasmussen T, Kastrup J, Knudsen LM, Johnsen HE. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma. Br J Haematol. 1999;105(1):265\u20137.","journal-title":"Br J Haematol"},{"issue":"12","key":"1683_CR111","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","volume":"125","author":"AC Rawstron","year":"2015","unstructured":"Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, Owen RG. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932\u20135. https:\/\/doi.org\/10.1182\/blood-2014-07-590166.","journal-title":"Blood"},{"issue":"4","key":"1683_CR112","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1172\/JCI66517","volume":"123","author":"AM Roccaro","year":"2013","unstructured":"Roccaro AM, Sacco A, Maiso P, Azab AK, Tai Y-T, Reagan M, Weller E. BM mesenchymal stromal cell\u2013derived exosomes facilitate multiple myeloma progression. J Clin Investig. 2013;123(4):1542.","journal-title":"J Clin Investig"},{"issue":"26","key":"1683_CR113","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1182\/blood-2009-01-198408","volume":"113","author":"AM Roccaro","year":"2009","unstructured":"Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Ghobrial IM. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113(26):6669\u201380. https:\/\/doi.org\/10.1182\/blood-2009-01-198408.","journal-title":"Blood"},{"issue":"2","key":"1683_CR114","doi-asserted-by":"publisher","first-page":"238","DOI":"10.18433\/J3989X","volume":"16","author":"A Roseblade","year":"2013","unstructured":"Roseblade A, Luk F, Rawling T, Ung A, Grau GE, Bebawy M. Cell-derived microparticles: new targets in the therapeutic management of disease. J Pharm Pharm Sci. 2013;16(2):238\u201353.","journal-title":"J Pharm Pharm Sci"},{"key":"1683_CR115","doi-asserted-by":"crossref","unstructured":"San Miguel, J. F., Guti\u00e9rrez, N. C., Mateo, G., & Orfao, A. (2006). Conventional diagnostics in multiple myeloma. European journal of cancer (Oxford, England : 1990), 42(11), 1510\u20131519.","DOI":"10.1016\/j.ejca.2005.11.039"},{"key":"1683_CR116","unstructured":"Sanderson, R. D., Borset, M., Lacy, H. M., Yang, Y., Liu, W., Bayer-Garner, I. B., & Wilson, C. S. Syndecan-1: A Multifunctional Regulator of Myeloma Cell Behavior. proteins, 96, 2528\u20132536."},{"issue":"2","key":"1683_CR117","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/sj.bmt.1701055","volume":"21","author":"G Schiller","year":"1998","unstructured":"Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu C, Lill M. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant. 1998;21(2):141\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"1683_CR118","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood.V96.9.3139","volume":"96","author":"C Seidel","year":"2000","unstructured":"Seidel C, B\u00f8rset M, Hjertner \u00d8, Cao D, Abildgaard N, Hjorth-Hansen H, Sundan A. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood. 2000;96(9):3139\u201346.","journal-title":"Blood"},{"issue":"2","key":"1683_CR119","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood.V95.2.388","volume":"95","author":"C Seidel","year":"2000","unstructured":"Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IMS, Abildgaard N, B\u00f8rset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2000;95(2):388\u201392.","journal-title":"Blood"},{"issue":"1","key":"1683_CR120","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21332.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1683_CR121","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ncb1800","volume":"10","author":"J Skog","year":"2008","unstructured":"Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470\u20136. https:\/\/doi.org\/10.1038\/ncb1800.","journal-title":"Nat Cell Biol"},{"key":"1683_CR122","doi-asserted-by":"publisher","unstructured":"Sonneveld, P., Durie, B. G., Lokhorst, H. M., Marie, J. P., Solbu, G., Suciu, S., . . . Nooter, K. (1992). Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet, 340(8814), 255\u2013259. doi:https:\/\/doi.org\/10.1016\/0140-6736(92)92353-h","DOI":"10.1016\/0140-6736(92)92353-h"},{"issue":"23","key":"1683_CR123","doi-asserted-by":"publisher","first-page":"14713","DOI":"10.1074\/jbc.272.23.14713","volume":"272","author":"SV Subramanian","year":"1997","unstructured":"Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of syndecan-1 and-4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem. 1997;272(23):14713\u201320.","journal-title":"J Biol Chem"},{"issue":"3","key":"1683_CR124","first-page":"131","volume":"30","author":"J Tate","year":"2009","unstructured":"Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay\u2013analytical issues. Clin Biochem Rev. 2009;30(3):131\u201340.","journal-title":"Clin Biochem Rev"},{"issue":"3","key":"1683_CR125","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1111\/bjh.16484","volume":"189","author":"JF Thompson","year":"2020","unstructured":"Thompson JF, Teh Z, Chen Y, Gardiner J, Bednarz JM, Thompson GN, Yeung D. A costing study of bortezomib shows equivalence of its real-world costs to conventional treatment. Br J Haematol. 2020;189(3):e76\u20139. https:\/\/doi.org\/10.1111\/bjh.16484.","journal-title":"Br J Haematol"},{"issue":"2A","key":"1683_CR126","first-page":"1107","volume":"28","author":"B Toth","year":"2008","unstructured":"Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P, Friese K. Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res. 2008;28(2A):1107\u201312.","journal-title":"Anticancer Res"},{"key":"1683_CR127","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/250476","volume":"2010","author":"AF Tramontano","year":"2010","unstructured":"Tramontano AF, Lyubarova R, Tsiakos J, Palaia T, Deleon JR, Ragolia L. Circulating endothelial microparticles in diabetes mellitus. Mediators Inflamm. 2010;2010: 250476. https:\/\/doi.org\/10.1155\/2010\/250476.","journal-title":"Mediators Inflamm"},{"issue":"6","key":"1683_CR128","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654\u20139. https:\/\/doi.org\/10.1038\/ncb1596.","journal-title":"Nat Cell Biol"},{"key":"1683_CR129","doi-asserted-by":"crossref","unstructured":"Wallington-Beddoe, C. T., & Coghlan, D. W. (2018). Resistance Mechanisms to Novel Therapies in Myeloma. Update on Multiple Myeloma.","DOI":"10.5772\/intechopen.77004"},{"issue":"4","key":"1683_CR130","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","volume":"124","author":"J Wang","year":"2014","unstructured":"Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Menu E. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124(4):555\u201366.","journal-title":"Blood"},{"issue":"1","key":"1683_CR131","doi-asserted-by":"publisher","first-page":"e0147360","DOI":"10.1371\/journal.pone.0147360","volume":"11","author":"X Wei","year":"2016","unstructured":"Wei X, Liu C, Wang H, Wang L, Xiao F, Guo Z, Zhang H. Surface Phosphatidylserine Is Responsible for the Internalization on Microvesicles Derived from Hypoxia-Induced Human Bone Marrow Mesenchymal Stem Cells into Human Endothelial Cells. PLoS ONE. 2016;11(1):e0147360.","journal-title":"PLoS ONE"},{"issue":"1","key":"1683_CR132","doi-asserted-by":"publisher","first-page":"22519","DOI":"10.1038\/srep22519","volume":"6","author":"E Willms","year":"2016","unstructured":"Willms E, Johansson HJ, M\u00e4ger I, Lee Y, Blomberg KEM, Sadik M, Vader P. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci Rep. 2016;6(1):22519. https:\/\/doi.org\/10.1038\/srep22519.","journal-title":"Sci Rep"},{"issue":"1","key":"1683_CR133","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.3402\/jev.v4.27066","volume":"4","author":"M Y\u00e1\u00f1ez-M\u00f3","year":"2015","unstructured":"Y\u00e1\u00f1ez-M\u00f3 M, Siljander PR-M, Andreu Z, BedinaZavec A, Borr\u00e0s FE, Buzas EI, Carvalho J. Biological properties of extracellular vesicles and their physiological functions. Journal of extracellular vesicles. 2015;4(1):27066.","journal-title":"Journal of extracellular vesicles"},{"issue":"22","key":"1683_CR134","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1200\/jco.2003.06.001","volume":"21","author":"HH Yang","year":"2003","unstructured":"Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol. 2003;21(22):4239\u201347. https:\/\/doi.org\/10.1200\/jco.2003.06.001.","journal-title":"J Clin Oncol"},{"key":"1683_CR135","doi-asserted-by":"crossref","unstructured":"Zhong, Y., Li, H., Li, P., Chen, Y., Zhang, M., Yuan, Z., . . . Fang, Y. (2021). Exosomes: a new pathway for cancer drug resistance. Frontiers in Oncology, 11.","DOI":"10.3389\/fonc.2021.743556"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-022-01683-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T19:07:45Z","timestamp":1702321665000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-022-01683-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1186\/s12943-022-01683-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"4 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Sydney Local Health District Human Research Ethics Committee (HREC) of Concord Repatriation General Hospital (CRGH) (HREC\/11\/CRGH\/223-CH62\/6\/2011\u2013150), Royal Prince Alfred Hospital HREC (SSA\/12\/RPAH\/10), and Human Research Ethics Committee at University of Technology Sydney (2012-004R).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\u2019 approval and consent to participate"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}